Press Release

NORCROSS, Ga., Dec. 1, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today that James C. Czirr, executive chairman of the Company's board of directors, will present at the LD Micro "Main Event" Micro-Cap Growth Conference on Wednesday, December 3, 2014 at 11:30 a.m. PST at the Luxe Sunset Bel Air Hotel in Los Angeles, Calif.

The presentation will include a Company overview and financial briefing, a summary of key accomplishments from 2014 including a review of the Company's Phase 1 clinical trial of GR-MD-02 in fatty liver disease with advanced fibrosis, and a discussion of upcoming milestones in 2015.

Czirr noted, "This year has been a particularly exciting time for Galectin Therapeutics, as we complete the Phase 1 clinical trial of our propriety galectin inhibitor in fatty liver disease, a condition affecting between nine and 15 million Americans. Liver transplantation is currently the only therapeutic approach to fatty liver disease or other forms of liver fibrosis as there are no drug therapies on the market. What we have seen in our Phase 1 trial is that GR-MD-02 is safe and well tolerated at multiple doses. We also found a reduction for serum biomarker alpha-2 macroglobulin, a key indicator in liver fibrosis. This data was presented by Stephen A. Harrison, M.D., Chief of Hepatology at Brooke Army Medical Center, at the American Association for the Study of Liver Diseases' The Liver Meeting, which represents the largest and most prestigious liver meeting in the world, attended by thousands of physicians, scientists and researchers from around the globe. We believe that galectin inhibition plays a role in liver fibrosis, and our upcoming Phase 2 clinical trial will increase our scientific understanding of this galectin effect."

Czirr will be available for one-on-one meetings on the day of the presentation. His presentation will be available as a live and archived webcast at the following address: http://wsw.com/webcast/ldmicro7/galt.

About LD Micro

LD Micro is an investment newsletter firm that focuses on finding undervalued companies in the micro-cap space. Since 2002, the firm has published reports on select companies throughout the year. The firm hosts the LD Micro "Main Event" Micro-Cap Growth Conference for investors in December of each year. This year's conference will feature presentations by over 240 publicly traded companies and is expected to attract more than 1,000 attendees. For additional information, please visit the LD Micro conference website at http://www.ldmicro.com.

About Galectin Therapeutics

Galectin Therapeutics (Nasdaq:GALT) is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, key mediators of biologic function. We are leveraging extensive scientific and development expertise as well as established relationships with external sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer. Additional information is available at www.galectintherapeutics.com.

Forward-Looking Statements

This press release contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as "may," "estimate," "could," "expect" and others. They are based on our current expectations and are subject to factors and uncertainties which could cause actual results to differ materially from those described in the statements. These statements include those regarding our plans, expectations and goals regarding clinical trials, including our expectation that a final clinical data report from the third cohort should be available in January 2015, plans regarding design and composition and timing of a Phase 2 clinical trial, and plans regarding future funding alternatives and the sufficiency of cash on hand to fund future operations and planned research and development through mid-2016. Factors that could cause our actual performance to differ materially from those discussed in the forward-looking statements include, among others, that our plans, expectations and goals regarding any clinical trial or any future trials are subject to factors beyond our control and there is no guarantee that we will avoid delays in the development of our drug products or receive FDA approval for any of our drugs in development. Any current clinical trials and any future trials may not produce positive results in a timely fashion, if at all, and any necessary changes during the course of a trial could prove time consuming and costly. We may have difficulty in enrolling candidates for testing, which would impact our estimates regarding timing, and we may not be able to achieve the desired results. Upon receipt of FDA approval, we may face competition with other drugs and treatments that are currently approved or those that are currently in development, which could have an adverse impact on our ability to achieve revenues from any proposed indications. Plans regarding development, approval and marketing of any of our drugs, including GR-MD-02, are subject to change at any time based on the changing needs of our company as determined by management and regulatory agencies. To date, we have incurred operating losses since our inception, and our ability to successfully develop and market drugs may be impacted by our ability to manage costs and finance our continuing operations. For a discussion of additional factors impacting our business, see our Annual Report on Form 10-K for the year ended December 31, 2013, and our subsequent filings with the SEC.  You should not place undue reliance on forward-looking statements. Although subsequent events may cause our views to change, we disclaim any obligation to update forward-looking statements.

CONTACT: Galectin Therapeutics Inc.

         Peter G. Traber, MD, 678-620-3186

         President, CEO, & CMO

         ir@galectintherapeutics.com